• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物处置研究的目的和时间安排,附录II。给狗服用羟基保泰松或其磷酸酯的钙盐或钠盐后血浆中羟基保泰松的浓度。

The objective and timing of drug disposition studies, appendix II. Plasma concentrations of oxyphenbutazone in dogs given oxyphenbutazone or the calcium or sodium salts of its phosphate ester.

作者信息

Hook R H, Eastwood C J, Wright G J

出版信息

Drug Metab Rev. 1975;4(2):249-65. doi: 10.3109/03602537508993759.

DOI:10.3109/03602537508993759
PMID:1222682
Abstract

Plasma levels of oxyphenbutazone were measured in beagle dogs following oral administration of oxyphenbutazone and salts of oxyphenbutazone phosphate. Dosage with sodium and calcium salts of oxyphenbutazone phosphate produced higher oxyphenbutazone plasma levels than dosage with oxyphenbutazone itself. Oxyphenbutazone phosphate was not detected in plasma following oral dosing with salts of oxyphenbutazone phosphate but was found in plasma following intramuscular administration of oxyphenbutazone phosphate sodium salt. A metabolite, oxyphenbutazone glucuronide, was found in plasma of dogs following administration of either oxyphenbutazone or salts of oxyphenbutazone phosphate.

摘要

在比格犬口服奥昔芬布宗及其磷酸奥昔芬布宗盐后,测定其血浆中奥昔芬布宗的水平。给予磷酸奥昔芬布宗的钠盐和钙盐后,血浆中奥昔芬布宗的水平高于给予奥昔芬布宗本身。口服磷酸奥昔芬布宗盐后,血浆中未检测到磷酸奥昔芬布宗,但肌肉注射磷酸奥昔芬布宗钠盐后,血浆中发现了该物质。给予奥昔芬布宗或磷酸奥昔芬布宗盐后,在犬的血浆中发现了一种代谢产物——奥昔芬布宗葡萄糖醛酸苷。

相似文献

1
The objective and timing of drug disposition studies, appendix II. Plasma concentrations of oxyphenbutazone in dogs given oxyphenbutazone or the calcium or sodium salts of its phosphate ester.药物处置研究的目的和时间安排,附录II。给狗服用羟基保泰松或其磷酸酯的钙盐或钠盐后血浆中羟基保泰松的浓度。
Drug Metab Rev. 1975;4(2):249-65. doi: 10.3109/03602537508993759.
2
Plasma and serum concentrations of phenylbutazone and oxyphenbutazone in racing Thoroughbreds 24 hours after treatment with various dosage regimens.采用不同给药方案治疗后24小时,赛马中保泰松和羟基保泰松的血浆及血清浓度。
Am J Vet Res. 1985 Apr;46(4):932-8.
3
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
4
Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys.保泰松及其代谢物羟基保泰松在临床正常马匹和驴体内的比较药代动力学。
Am J Vet Res. 1997 Jan;58(1):53-5.
5
[Comparison of bumadizone-, phenylbutazone- and oxyphenbutazone-plasma levels after a single oral dose of phenylbutazone and of bumadizone, respectively (author's transl)].分别单次口服保泰松和布马地宗后布马地宗、保泰松和羟基保泰松血浆水平的比较(作者译)
Arzneimittelforschung. 1981;31(3):499-503.
6
Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration.静脉注射、肌肉注射和口服给药后,苯基布他松在牛体内的药代动力学、代谢和排泄情况。
Res Vet Sci. 1988 Jan;44(1):57-67.
7
Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses.
Res Commun Chem Pathol Pharmacol. 1979 Jun;24(3):465-82.
8
Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs.一种新型强效肝素的特性。第六篇通讯:新型强效肝素钠盐和钙盐在比格犬皮下注射后的抗凝效果比较。
Arzneimittelforschung. 1981;31(1):79-82.
9
The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.抗蠕虫药甲基-14C-5-环丙基羰基-2-苯并咪唑氨基甲酸酯(环苯达唑)对大鼠和犬给药后的放射性分布情况。
Arzneimittelforschung. 1977;27(3):593-8.
10
Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
Arzneimittelforschung. 1997 Feb;47(2):169-74.